Allogeneic Stem Cell Transplant
MT2023-20: Hematopoietic Cell Transplant With Reduced Intensity Conditioning and Post-transplant Cyclophosphamide for Severe Aplastic Anemia and Other Forms of Acquired Bone Marrow Failure.
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 2
- Enrollment
- 60 patients (estimated)
- Sponsors
- University of Minnesota - Masonic Cancer Center
- Tags
- Allogeneic Stem Cell Transplant
- Trial Type
- Treatment
- Last Update
- 2 months ago
- SparkCures ID
- 1917
- NCT Identifier
- NCT06412497
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.